glp 1 market Obesity GLP-1 GLP-1 Drug Market: the rapid

11 (Suppl

Tirzepatide 15 mg was also associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59], I 2 0%) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85], I 2 52%), while more participants receiving tirzepatide 10 mg experienced vomiting (OR 2.98 [95% CI 1.13, 7.80], I 2 0%) (Table 2)

For example, Novo Nordisk's Rybelsus has accelerated the adoption of oral GLP-1 therapies across multiple healthcare markets

Rapid Weight Loss When weight changes quickly, the body diverts energy toward essential functions

Injecting into wet skin can cause stinging

Although this has been found to be the case, it was also found that other preprocedural GI effects were observed with a higher incidence in GLP-1 RA users such as reduced gastric acidity, nausea, vomiting, dyspepsia, and abdominal distension (OR 15.1